NeurAxis, Inc. (NRXS) Stock

NeurAxis, Inc. (NRXS) is a Healthcare stock trading at $7.17 (as of 2026-06-18), with a market capitalization of $91.77M and a trailing P/E of -9.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

NeurAxis, Inc. is a neuromodulation therapy device company that develops IB-Stim, a percutaneous electrical nerve field stimulation system for patients ages 11–18 with functional abdominal pain associated with irritable bowel syndrome. Its target customers include healthcare providers such as hospitals and clinics.

Valuation — source: SEC EDGAR (first-party)
Price	$7.17
Market Cap	$91.77M
P/E Ratio	-9.3
EV / EBITDA	-11.8
Price / Book	15.97
Price / Sales	21.43
DCF Value (model)	$-9.41
DCF Upside vs Price	-231.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$3.57M
Net Margin	-218.5%
Return on Equity	-126.7%
Debt / Equity	0.02
Current Ratio	2.89
Revenue Growth (YoY)	32.9%
EPS Growth (YoY)	-22.1%
FCF Growth (YoY)	5.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	-1.03 (distress)
Piotroski F-Score	4/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	-9.3
Sector P/E (Healthcare)	21.0
Industry P/E (Medical Equipment)	31.7
vs Sector	-144.2%
vs Industry	-129.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	AIGH Capital Management LLC ($2.96M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Brian Carrico
Employees	21
Country	US
IPO Date	2023-08-09

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.